Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
Combined central and peripheral demyelination: Clinical features, diagnostic findings, and treatment.
Pediatric multiple sclerosis.
A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial.
Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination.
Assessment of statistical significance and clinical relevance.
Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
Gait variability measures reveal differences between multiple sclerosis patients and healthy controls.
Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord.
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
Early relapses, onset of progression, and late outcome in multiple sclerosis.
Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica.
Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.
Combination Treatment of Interferon β-1b and Warfarin for a Patient With Baló's Concentric Sclerosis and Antiphospholipid Syndrome.
Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects.
The Stigma Scale for Chronic Illnesses 8-Item Version (SSCI-8): Development, Validation and Use Across Neurological Conditions.
Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells.
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Prospective memory, emotional valence, and multiple sclerosis.
Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.
Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1R ) and receptor-5 (S1P5R ) agonist with autoimmune disease-modifying activity.

Pages